Gordian Biotechnology

Stage: Series A

Get updates & announcements

About

The Gordian platform Gordian uses a proprietary in vivo drug discovery platform to identify targets and therapies for complex age-related diseases that are most likely to succeed in human trials.

Contact Details

https://www.gordian.bio/contact/

https://www.gordian.bio/

https://www.gordian.bio/blog/

Community Affiliations

Members (1)

Martin Borch Jensen

CSO

Focus Areas

Projects

Add projects associated with this team.

Gordian Biotechnology News (4)

Gordian Biotechnology researchers co-author study finding low-dose GLP-1 drugs protect…

A Cedars-Sinai–led study in the European Heart Journal, with multiple Gordian researchers as co-authors, found that low-dose semaglutide reduces cardiac stiffness, enlargement, and scarring in animal models without cutting body weight.

Announcement13d ago

1 Views

Gordian Biotechnology Presents at Biomarkers of Aging Conference at Harvard

Martin Borch Jensen of Gordian Biotechnology spoke on AI models and causal atlases of age-related disease at the fourth annual Biomarkers of Aging Conference.

Otherlifespan.io21d ago

3 Views

Gordian names first drug candidate, Omen 13, for osteoarthritis

The gene-therapy candidate entered IND-enabling studies after screening ~200 targets in horses and validating hits in human joint tissue.

Announcement3 months ago

10 Views

All network updates